세계의 감염증 관리 시장 예측(-2032년) : 제품별, 유형별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Infectious Disease Management Market is accounted for $23.3 billion in 2025 and is expected to reach $38.9 billion by 2032 growing at a CAGR of 7.6% during the forecast period. Infectious disease management refers to the comprehensive approach used to prevent, diagnose, treat, and control diseases caused by pathogens such as bacteria, viruses, fungi, and parasites. It involves surveillance, early detection through diagnostic tools, timely medical intervention, and public health strategies to limit transmission. Vaccination programs, antimicrobial therapies, and quarantine measures are key components. Effective management also includes education, sanitation, and global collaboration to address outbreaks and pandemics. With advancements in biotechnology and data analytics, infectious disease management has become more proactive, enabling healthcare systems to respond swiftly and reduce the impact of contagious illnesses on populations.

Market Dynamics:

Driver:

Rising global infectious risks

The increasing prevalence of infectious diseases worldwide is a major driver of the market. Frequent outbreaks of viruses like COVID-19, influenza, and emerging pathogens have heightened global awareness and demand for robust disease control systems. Governments and healthcare providers are investing in surveillance, diagnostics, and treatment infrastructure to mitigate risks. This growing urgency to contain and prevent infections is fueling innovation and expansion in the market, making infectious disease management a top priority across regions.

Restraint:

High cost of advanced diagnostics

The high cost of advanced diagnostic tools poses a significant restraint to market growth. Technologies such as molecular testing, genomic sequencing, and rapid diagnostics require substantial investment in equipment, training, and maintenance. These expenses can be prohibitive for healthcare systems in low- and middle-income countries, limiting access to timely and accurate disease detection. As a result, disparities in healthcare infrastructure and affordability hinder the widespread adoption of effective infectious disease management solutions, slowing market penetration.

Opportunity:

Advancements in diagnostics

Technological advancements in diagnostics offer a promising opportunity for the market. Innovations like point-of-care testing, AI-driven analysis and portable diagnostic devices enable faster, more accurate detection of pathogens. These tools improve patient outcomes by facilitating early intervention and reducing transmission. As healthcare systems embrace digital transformation and personalized medicine, the demand for cutting-edge diagnostics continues to rise. This trend is expected to drive significant growth and reshape the landscape of infectious disease management.

Threat:

Regulatory hurdles

Regulatory hurdles present a notable threat to the market. Stringent approval processes for new diagnostics, treatments, and vaccines can delay product launches and limit access during critical outbreaks. Compliance with varying international standards adds complexity for manufacturers and healthcare providers. These challenges may slow innovation and hinder timely responses to emerging health threats. Addressing regulatory bottlenecks through streamlined policies and global collaboration is essential to ensure rapid deployment of effective disease management solutions.

Covid-19 Impact:

The Covid-19 pandemic had a profound impact on the infectious disease management market, accelerating demand for diagnostics, vaccines, and treatment solutions. It exposed gaps in global healthcare infrastructure and emphasized the need for rapid response systems. Governments and organizations invested heavily in research, testing, and public health initiatives, driving innovation and collaboration. The pandemic also spurred adoption of digital health technologies and telemedicine. While it disrupted supply chains and strained resources, Covid-19 ultimately reshaped the market with lasting improvements.

The vaccines segment is expected to be the largest during the forecast period

The vaccines segment is expected to account for the largest market share during the forecast period because Vaccines play a crucial role in preventing the spread of infectious diseases and reducing healthcare burdens. The success of COVID-19 vaccination campaigns has reinforced their importance, prompting increased investment and development. Advances in mRNA technology, global immunization programs, and rising public awareness contribute to the segment's growth. As new pathogens emerge, vaccines remain a cornerstone of proactive disease management and public health strategy.

The fungal infections segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the fungal infections segment is predicted to witness the highest growth rate, due to rising cases of fungal diseases, particularly among immune compromised individuals, are driving demand for specialized diagnostics and treatments. Climate change, antibiotic resistance, and increased hospitalizations contribute to the growing prevalence of fungal infections. Innovations in antifungal therapies and improved detection methods are enhancing patient care. As awareness and research expand, the market for managing fungal infections is expected to grow rapidly, outpacing other segments.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to region's dense population, frequent outbreaks, and expanding healthcare infrastructure drive demand for effective disease control solutions. Countries like China, India, and Japan are investing in diagnostics, vaccination programs, and public health initiatives. Government support, rising awareness, and technological adoption further boost market growth. Asia Pacific's strategic focus on infectious disease preparedness positions it as a dominant force in the global market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to region's strong healthcare infrastructure, advanced research capabilities, and proactive public health policies support rapid innovation. High demand for personalized medicine, digital diagnostics, and vaccine development fuels growth. Investments in biotechnology and collaborations between government and private sectors enhance market expansion. As North America continues to lead in technological advancements and disease surveillance, its infectious disease management market is set to surge.

Key players in the market

Some of the key players in Infectious Disease Management Market include Pfizer, Gilead Sciences, Johnson & Johnson, Merck & Co., GlaxoSmithKline (GSK), Roche, Sanofi, Novartis, AstraZeneca, AbbVie, Takeda Pharmaceutical, BioNTech, Moderna, Eli Lilly and Company and Bayer AG.

Key Developments:

In March 2025, Harbour BioMed and AstraZeneca have embarked on a global collaboration to discover and develop next-generation multi-specific antibodies targeting immunology, oncology, and other therapeutic areas.

In March 2025, Bayer and Neste entered a strategic partnership to develop winter canola as a sustainable feedstock for renewable fuels. This collaboration aims to establish a U.S.-based winter canola ecosystem, enhancing soil health and carbon sequestration.

Products Covered:

• Diagnostics
• Therapeutics
• Vaccines

Types Covered:

• Bacterial Infections
• Viral Infections
• Fungal Infections
• Parasitic Infections

End Users Covered:

• Hospitals
• Diagnostic Laboratories
• Ambulatory Care Centers
• Research & Academic Institutes
• Home Healthcare
• Digital Health Solutions
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Infectious Disease Management Market, By Product

• 5.1 Introduction
• 5.2 Diagnostics
  • 5.2.1 PCR & Molecular Diagnostics
  • 5.2.2 Immunoassays
  • 5.2.3 Rapid Test Kits
• 5.3 Therapeutics
  • 5.3.1 Antibiotics
  • 5.3.2 Antivirals
  • 5.3.3 Antifungals
  • 5.3.4 Antiparasitic Drugs
• 5.4 Vaccines
  • 5.4.1 Viral Vaccines
  • 5.4.2 Bacterial Vaccines

6 Global Infectious Disease Management Market, By Type

• 6.1 Introduction
• 6.2 Bacterial Infections
  • 5.2.1 Tuberculosis
  • 5.2.2 Pneumonia
• 6.3 Viral Infections
  • 5.3.1 HIV/AIDS
  • 5.3.2 Influenza
  • 5.3.3 Hepatitis
  • 5.3.4 COVID-19
• 6.4 Fungal Infections
• 6.5 Parasitic Infections

7 Global Infectious Disease Management Market, By End User

• 7.1 Introduction
• 7.2 Hospitals
• 7.3 Diagnostic Laboratories
• 7.4 Ambulatory Care Centers
• 7.5 Research & Academic Institutes
• 7.6 Home Healthcare
• 7.7 Digital Health Solutions
• 7.8 Other End Users

8 Global Infectious Disease Management Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Pfizer
• 10.2 Gilead Sciences
• 10.3 Johnson & Johnson
• 10.4 Merck & Co.
• 10.5 GlaxoSmithKline (GSK)
• 10.6 Roche
• 10.7 Sanofi
• 10.8 Novartis
• 10.9 AstraZeneca
• 10.10 AbbVie
• 10.11 Takeda Pharmaceutical
• 10.12 BioNTech
• 10.13 Moderna
• 10.14 Eli Lilly and Company
• 10.15 Bayer AG